Skip to main content
Premium Trial:

Request an Annual Quote

Riken STAP Researcher Resigns

Riken's Haruko Obokata has resigned after efforts to replicate her approach for reprogramming cells to an embryonic-like state failed.

In now-retracted papers published in Nature nearly a year ago, Obokata and her colleagues claimed to be able revert differentiated cells to a pluripotent state by exposing them to a strong stimulus like low pH, a phenomenon dubbed stimulus-triggered acquisition of pluripotency, or STAP. Critics soon began to point out inconsistencies in images in the papers and questioned the methodology; a number of labs said they couldn't repeat the findings.

Riken also launched an investigation, which identified instances of fabrication and falsification, and found Obokata guilty of research misconduct. Its independent team also could not replicate the STAP approach, though continued to try different cells under various conditions.

Those efforts, even with Obokata's subsequent help, Riken now says have failed, ScienceInsider reports.

"Dr. Obokata has been unable to reproduce the … phenomenon," Shinichi Aizawa, who was leading the Riken verification team, said during a press conference according to the Wall Street Journal. "While we initially planned to continue efforts until March, we will end the experiments at this point."

In the wake of this announcement, Obokata has resigned. In a statement, Obokata says that she is "very puzzled by these results."

ScienceInsider notes that there are still "a number of lingering questions" regarding this case, including why none of Obokata's co-authors tested the approach in their labs and why the papers were accepted by Nature after being rejected by Science and Cell, and receiving unfavorable reviews from Nature's own reviewers.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.